ESICORT

Main information

Trade name:
ESICORT 10 F.

Active ingredient:
Escitalopram,Clonazepam

Available from:
LA DRUG

Dosage:
10,0.5;MG

Pharmaceutical form:
F.

Composition:
10

Medicine domain:
Humans

Medicine type:
Allopathic drug

Documents

for the general public:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

for healthcare professionals:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for healthcare professionals.

Localization

Available in:
India

Language:
English

Other information

Status

Source:
Central Drugs Standard Control Organization

Last update:
09-08-2016

The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

Access to this document is only available to registered users.

Register now for full access

15-5-2018

May 7, 2018: Abingdon Nurse Practitioner Pleads Guilty to Conspiring to Illegally Prescribe Buprenorphine, Clonazepam, and Gabapentin at Substance Abuse Treatment Program

FDA - U.S. Food and Drug Administration

3-1-2012

Danish Pharmacovigilance Update, 15 December 2011

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), and new recommendations for the antidepressant escitalopram.

Danish Medicines Agency

7-10-2011

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelat...